Core Viewpoint - Rosen Law Firm is reminding investors who purchased Capricor Therapeutics, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on September 15, 2025 [1]. Group 1: Class Action Details - Investors who purchased Capricor securities between October 9, 2024, and July 10, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by September 15, 2025 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting their own achievements in this area [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. - Rosen Law Firm has been recognized for its leadership in securities class action settlements, ranking No. 1 in 2017 and consistently in the top 4 since 2013 [4]. Group 3: Case Specifics - The lawsuit alleges that Capricor provided misleading information regarding its lead cell therapy candidate, deramiocel, which is intended for treating cardiomyopathy associated with Duchenne muscular dystrophy [5]. - Defendants allegedly made positive statements about obtaining a Biologics License Application from the FDA while concealing adverse facts about the drug's safety and efficacy data from its Phase 2 trial [5]. - This misleading information is claimed to have caused shareholders to purchase securities at inflated prices, leading to investor damages when the truth was revealed [5].

NEW YORK, Aug. 30, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Alto Neuroscience, Inc. (NYSE: ANRO): (i) pursuant and/or traceable to Alto’s initial public offering conducted on or about February 2, 2024 (the “IPO”); and/or (ii) securities between February 2, 2024 and October 22, 2024, both dates inclusive (the “Class Period”), of the important September 19, 2025 lead plaintiff deadline. SO WHAT: If you purchased Alto securities you ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Altimmune, Inc. securities between August 10, 2023, and June 25, 2025, about the October 6, 2025, deadline to become a lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - A class action lawsuit has been filed against Altimmune, and investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][2] - To participate in the class action, investors can submit a form or contact the law firm for more information [2][5] - The lawsuit claims that Altimmune misrepresented the results of its IMPACT Phase 2b MASH trial, leading to investor damages when the true results were revealed [4] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [3] - The firm has been consistently ranked among the top firms for securities class action settlements since 2013, recovering hundreds of millions for investors [3] - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in litigation [3]

Core Insights - LEQEMBI IQLIK is the first and only anti-amyloid treatment that allows for at-home injections, enabling patients and care partners to continue treatment after an initial 18-month intravenous therapy [1][2] - The U.S. FDA has approved the Biologics License Application for LEQEMBI IQLIK, which will be launched on October 6, 2025 [2][11] - The treatment is indicated for maintenance dosing in patients with mild cognitive impairment or mild dementia, following an initial 18-month intravenous treatment [2][16] Group 1: Treatment Mechanism and Efficacy - LEQEMBI targets both amyloid plaques and protofibrils, which are believed to contribute to cognitive decline in Alzheimer's disease [4][12] - Clinical trials indicate that transitioning to the weekly LEQEMBI IQLIK autoinjector after 18 months maintains clinical and biomarker benefits comparable to continued intravenous dosing [5][40] - In the Clarity AD core study, treatment with lecanemab reduced clinical decline on the Clinical Dementia Rating Sum of Boxes (CDR-SB) by 27% at 18 months compared to placebo [40] Group 2: Safety and Side Effects - The safety profile of LEQEMBI IQLIK is similar to that of intravenous treatment, with fewer systemic reactions reported [5][37] - Injection-related adverse events were less common with subcutaneous dosing, occurring in less than 1% of patients compared to approximately 26% with intravenous infusions [5][37] - The incidence of amyloid-related imaging abnormalities (ARIA) was similar between patients receiving the subcutaneous maintenance dose and those continuing with intravenous dosing [5][20] Group 3: Patient Support and Accessibility - Eisai offers various patient support programs in the U.S. to assist patients and care partners with treatment navigation and insurance coverage [9][10] - The Patient Assistance Program (PAP) will provide LEQEMBI and LEQEMBI IQLIK at no cost for eligible uninsured and underinsured patients [10] - The subcutaneous formulation is expected to reduce healthcare resource utilization associated with intravenous maintenance dosing, streamlining the overall Alzheimer's treatment pathway [8]

THOUSAND OAKS, Calif., Aug. 29, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2025 Wells Fargo Healthcare Conference at 10:15 a.m. ET on Wednesday, Sept. 3, 2025. Paul Burton, M.D., Ph.D, senior vice president and chief medical officer at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.The webcast, as with other selected presentations regarding development ...

IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focu ...

Telix Pharmaceuticals Limited (NASDAQ: TLX ) has been in the news a fair bit recently. And I've remained positive despite the apparent setbacks that this company has faced. Today, let's contend with their latest round of bad news that hasI have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your due diligence and not get b ...

On Friday, the District Court for the Middle District of North Carolina issued a ruling invalidating specific claims in two patents that Natera Inc. NTRA asserted against NeoGenomics, Inc.'s NEO v1.1 RaDaR test.Natera said on Friday that it is evaluating its options, including an appeal and further enforcement with other patents.Natera said these patents are distinct from U.S. Patent No. 11,519,035 (the ‘035 patent), and the decision has no impact on the validity or enforceability of the ‘035 patent.The ‘03 ...

Key Takeaways CRSP's CTX310 showed up to 86% LDL and 82% TG reductions in early-stage study data.CRSP is developing CTX320 in an early-stage study for lipoprotein(a), tied to heart disease.The company plans to advance CTX340 and CTX450 into clinical studies by the end of 2025.CRISPR Therapeutics (CRSP) is the first and only company in the world to market a CRISPR/Cas9-based therapy. The company tasted major success with the approval of its one-shot gene therapy, Casgevy, in late 2023 and early 2024 across t ...

Company Overview - Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company focused on developing immune-modulating therapies for life-threatening conditions [2] - The lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, which has broad therapeutic potential [2] - The company is conducting preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS) [2] Upcoming Events - David-Alexandre C. Gros, M.D., CEO of Eledon, will participate in a fireside chat at the Cantor Global Healthcare Conference on September 5, 2025, at 9:10 a.m. ET [1] - A webcast replay of the fireside chat will be available on the company's website following the live session [1]